NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Bally Technologies ( BYI) upgraded at JP Morgan from Neutral to Overweight, JP Morgan said. Valuation call, based on a $47 price target.

Ctrip.com ( CTRP) downgraded to hold at TheStreet Ratings.

Salesforce.com ( CRM) downgraded at Cowen from Neutral to Underperform, Cowen said. Billings growth is decelerating.

Edwards Lifesciences ( EW - Get Report) upgraded at Canaccord from Hold to Buy, Canccord said. $75 price target. Robust TAVI pipeline update and strong guidance.

Fresh Del Monte Produce ( FDP) downgraded to hold at TheStreet Ratings.

Lennar ( LEN) downgraded at Keybanc from Buy to Hold, Keybanc said. Valuation call, as gross margin is at a historical high.

MetroPCS ( PCS) upgraded at Credit Suisse from Neutral to Outperform, Credit Suisse said. $10 price target. New spectrum should cut the company's costs.

PNM Resources ( PNM) downgraded at Wells Fargo from Outperform to Market Perform, Wells Fargo said. $17.50-18.50 price target. Concerns about New Mexico's regulatory environment will limit valuation expansion.

Scripps Networks Interactive ( SNI) rated new Equal Wieght at Evercore. $50 price target. Under priced with significant international opportunity.

Toll Brothers ( TOL - Get Report) downgraded at Keybanc from Buy to Hold, Keybanc said. Valuation call.

Tempur-Pedic ( TPX) upgraded at Oppenheimer from Perform to Outperform, Oppenheimer said. $70 price target. Investor concerns are overstated.

STOCK COMMENTS / EPS CHANGES

Accenture ( ACN) estimates boosted at Morgan Stanley through 2014. Company remains leveraged to secular growth trends. Overweight rating and $66 price target.

Amgen ( AMGN - Get Report) estimates, target increased at UBS. Shares of AMGN now seen reaching $59, according to UBS. Estimates also increased on updated share count, debt, and Enbrel. Neutral rating.

BP plc ( BP) estimates lowered at Oppenheimer. Shares of BP lowered through 2012, Oppenheimer said. Adjusted estimate based on futures oil and gas prices. Outperform rating.

CIT Group ( CIT) target cut at Citigroup to $44, Citigroup said. Widening in credit markets that undercuts refinancing efforts. Buy rating.

Columbia Sportswear ( COLM) numbers cut at Auriga. Shares of COLM now seen reaching $48, according to Auriga USA. Estimates also reduced, given warm weather in recent months. Hold rating.

DuPont ( DD) estimates lowered at Credit Suisse through 2013. Company is being hurt by slower macro growth. Neutral rating and $58 price target.

Elan ( ELN) estimates raised at Jefferies through 2012, Jefferies said. One of the top picks for 2012. Buy rating.

Endo Pharmaceuticals ( ENDP) estimates increased at Citigroup through 2012, Citigroup said. Robust Opana ER franchise. Maintain $48 price target and Buy rating.

Edwards Lifesciences ( EW - Get Report) numbers raised at Citigroup. Shares of EW now seen reaching $84, according to Citigroup. Estimates also increased ahead of FDA action on Opana. Buy rating.

Edwards Lifesciences estimates increased at Morgan Stanley through 2013, Morgan Stanley said. Core domestic sales remain strong. Equal-weight rating.

Halliburton ( HAL - Get Report) target reduced at Morgan Stanley to $52, according to Morgan Stanley. Market remains very competitive. Overweight rating.

Health Management Associates ( HMA) estimates lowered at UBS through 2012, UBS said. Required swap amortization of Term Loan B. Maintain $11.50 price target and Buy rating.

H&R Block ( HRB) target raised at Goldman to $16, according to Goldman Sachs. Company has a solid growth strategy, highlighted at the recent investor meeting. Neutral rating.

Harsco ( HSC) estimates lowered at Jefferies through 2012, Jefferies said. Guidance looks aggressive. Hold rating.

Intel ( INTC - Get Report) estimates lowered at UBS through 2012 on macro weakness, UBS said. Maintain $30 price target and Buy rating.

Nextera Energy ( NEE) estimates upped at Goldman through 2014, Goldman Sachs said. Company is buying back more stock. Neutral rating and $55 price target.

Nike ( NKE - Get Report) target boosted at Stifel. Shares of NKE now seen reaching $108. Company is raising prices and seeing more favorable exchange rates.

Onyx Pharmaceuticals ( ONXX) numbers cut at Goldman. Shares of ONXX now seen reaching $45. Estimates also reduced, as CFZ approval will likely be pushed out. Buy rating.

Verifone ( PAY) estimates, target increased at Goldman. PAY estimates were raised through 2013, Goldman Sachs said. Emerging markets should continue to drive growth. Neutral rating and new $43 price target.

Pall ( PLL) estimates, target raised at Credit Suisse. Shares of PLL now seen reaching $68, according to Credit Suisse. Estimates also increased, as the life sciences segment should continue to drive growth. Outperform rating.

Tesoro Logistics Partners ( TLLP) target raised at Oppenheimer. Shares of TLLP now seen reaching $34.50, Oppenheimer said. Raised after TLLP's 2012 business plan. Outperform rating.

United Technologies ( UTX) estimates lowered at UBS through 2012, UBS said. E&D, pension, and FX headwinds. Maintain $91 price target and Buy rating.

ExxonMobil ( symbol) estimates lowered at Oppenheimer through 2012, Oppenheimer said. Adjusted estimate based on changes i futures oil and gas prices. Outperform rating.

>To submit a news tip, email: tips@thestreet.com.

RELATED STORIES:


Follow TheStreet on Twitter and become a fan on Facebook.

This article was written by a staff member of RealMoney.com.